A Phase 2 Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW-3300 Administered Rectally for 12 Weeks to Treat Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Latest Information Update: 04 Mar 2025
At a glance
- Drugs IW-3300 (Primary)
- Indications Interstitial cystitis; Pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
Most Recent Events
- 26 Feb 2025 According to ClinicalTrials.gov record this trial is Terminated due to Business decision
- 26 Feb 2025 Status changed from active, no longer recruiting to discontinued.
- 04 Nov 2024 Planned End Date changed from 1 Nov 2025 to 1 Feb 2025.